Among the top targets identified from druggability analysis, four of them (i.e., DRD2, C4B, GABA-A-R, C5AR1) were shown in the single-nuclei sequencing data because of their clinical relevance to inflammation involved in Alzheimer’s disease. The gene discussed is C5AR1; the disease is early-onset autosomal dominant Alzheimer disease.